What did @masha.aho actually say?
Honestly, this is one of the harder videos to fact-check because the transcript is largely incoherent. The caption, written in Finnish, is doing more communicative work than the spoken content. Translated, it reads roughly: "The best side effect if you only have to endure it for a couple of days and don't have to keep enduring it!" Combined with the hashtags for constipation (ummetus) and mental health (mielenterveys), the creator appears to be describing a short-lived GLP-1 side effect, likely gastrointestinal, that resolved quickly.
The spoken transcript itself contains no extractable medical claim. It reads as fragmented, possibly auto-generated or mistranscribed speech. There are no direct quotes referencing medication names, dosing, or treatment outcomes. Any fact-checking here has to lean heavily on the caption context rather than verified spoken claims.
Does the science back this up?
If the creator is saying GLP-1 side effects can be short-lived and tolerable for some people, that is broadly supported by evidence. The framing that you might "only have to endure it for a couple of days" reflects real patient experience data, though it oversimplifies a more variable clinical picture.
The SUSTAIN and STEP trial programs for semaglutide consistently documented gastrointestinal adverse events, including nausea, vomiting, and constipation, as the most common reasons for discontinuation. Davies et al. (2021, Diabetes Care) found that nausea affected roughly 44% of participants on semaglutide 2.4mg, but for many it was transient, peaking in the first weeks and declining over time. Constipation, specifically, tends to be more persistent than nausea. Rubino et al. (2021, JAMA) reported constipation rates of around 24% in the Wegovy trial population, and it did not always resolve in days. So the "just a couple of days" framing may be accurate for some GI symptoms but is an understatement for constipation specifically.
What did they get wrong (or right)?
The creator gets partial credit for framing the side effect experience as individual and variable, which is accurate. GLP-1 tolerability genuinely differs person to person. That part deserves acknowledgment.
What is potentially misleading, even if unintentionally, is the implication that short duration is the norm. For a 60,000-view video aimed at people considering or starting GLP-1 therapy, this sets expectations that do not hold for every user. Wilding et al. (2021, New England Journal of Medicine) showed that a meaningful proportion of semaglutide users discontinued due to GI effects, suggesting those effects were not just "a couple of days" for everyone. Constipation in particular can be chronic and may require active management, including fiber intake adjustments, hydration, and in some cases medical intervention. The cheerful tone around "best side effect" could discourage people from reporting persistent symptoms to their prescriber, which would be a real clinical risk.
What should you actually know?
GLP-1 receptor agonists do have a well-characterized side effect profile, and some people do tolerate them easily. But the personal experience of one creator should not set your expectations for your own response. Side effects on these medications range from briefly annoying to clinically significant, and constipation specifically is one that warrants attention rather than dismissal.
A few things worth knowing if you are on or considering GLP-1 therapy:
- Nausea is the most reported side effect and often improves after dose titration, but it is not universal or brief for everyone.
- Constipation affects roughly one in four users in clinical trials and can persist beyond initial weeks.
- Serious GI complications, including gastroparesis, have been reported and are under ongoing regulatory review (FDA Drug Safety Communication, 2023).
- If you experience side effects that are not resolving, that is a clinical conversation, not a waiting game.
- No compounded semaglutide or tirzepatide product has demonstrated bioequivalence to FDA-approved branded formulations. Do not assume they behave identically.
Talk to a licensed provider before adjusting anything based on social media experience, including this one.